VIVOTIF Drug Profile

Summary for Tradename: VIVOTIF

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for VIVOTIF

Recent Clinical Trials for VIVOTIF

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University of Maryland, Baltimore	Phase 4
University of Maryland	Phase 4
International Centre for Diarrhoeal Disease Research, Bangladesh	Phase 1/Phase 2

See all VIVOTIF clinical trials

Pharmacology for VIVOTIF

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Live Attenuated Salmonella Typhi Vaccine
Chemical Structure	Vaccines, Attenuated Vaccines, Typhoid

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for VIVOTIF Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for VIVOTIF Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for VIVOTIF Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bavarian Nordic A/s	VIVOTIF	typhoid vaccine live oral ty21a	Capsule	103123	10,293,037	2032-07-05	Patent claims search
Bavarian Nordic A/s	VIVOTIF	typhoid vaccine live oral ty21a	Capsule	103123	10,441,645	2033-12-18	Patent claims search
Bavarian Nordic A/s	VIVOTIF	typhoid vaccine live oral ty21a	Capsule	103123	10,695,415	2035-07-06	Patent claims search
Bavarian Nordic A/s	VIVOTIF	typhoid vaccine live oral ty21a	Capsule	103123	10,815,455	2033-04-25	Patent claims search
Bavarian Nordic A/s	VIVOTIF	typhoid vaccine live oral ty21a	Capsule	103123	10,821,163	2036-07-13	Patent claims search

VIVOTIF Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Vivotif

Introduction to Vivotif

Vivotif, also known as Ty21a, is an oral typhoid vaccine that has been a cornerstone in the prevention of typhoid fever. Developed and initially marketed by Berna Biotech, it is now part of the portfolio of Bavarian Nordic, following an acquisition from Emergent BioSolutions.

Market Overview of TCV Vaccines

The global Typhoid Conjugate Vaccines (TCV) market, in which Vivotif is a key player, is experiencing significant growth. This market is projected to reach USD 935.9 million by 2031, growing at a Compound Annual Growth Rate (CAGR) of 12.4% from 2024 to 2031[1][4].

Market Share and Dominance of Vivotif

Vivotif dominates the TCV vaccines market due to its strong brand recognition and proven efficacy. In 2024, the Ty21a (Vivotif) segment is estimated to contribute the highest market share of 45.6%[1]. This dominance is attributed to its long history of safe administration and its ability to provide protective immunity comparable to injectable vaccines without the need for needles.

Distribution Channels and Market Reach

The distribution of Vivotif is predominantly through government initiatives and public health programs, which are crucial for its market reach. Retail pharmacies and healthcare institutions also play a significant role in the distribution, especially in regions where government programs are less prevalent[1].

Financial Performance of Vivotif

Following the acquisition by Bavarian Nordic, Vivotif has contributed significantly to the company's financial performance. In the second quarter of 2023, revenue from the sale of Vivotif was DKK 27 million, and for the first half of 2023, it was DKK 119 million, covering only the period from May 15, 2023, when the acquisition was completed[2][3].

Revenue Growth and Projections

The revenue from Vivotif is expected to grow as the travel health segment, which includes typhoid vaccines, experiences a rebound in international travel post-COVID-19. Bavarian Nordic's annual report for 2023 highlighted a 49% increase in the travel health business, which includes Vivotif and other vaccines like Rabipur and Encepur[3].

Challenges and Restraints

Despite the positive growth trajectory, the market for Vivotif faces challenges such as limited supply chains and varying regional demand. Additionally, the temporary stock-out situation in the fourth quarter of 2022 affected sales, although the product has shown strong recovery since then[3].

Strategic Acquisitions and Market Expansion

Bavarian Nordic's strategic acquisitions, including the purchase of Vivotif from Emergent BioSolutions, have diversified their commercial products and made the company more resilient to market challenges. This diversification is expected to drive further growth and improve market position in the travel vaccines sector[3].

Government Initiatives and Public Health Impact

Government initiatives and public health programs are key drivers for the TCV vaccines market, including Vivotif. Increasing awareness of typhoid's prevalence and the push to combat antibiotic resistance have led to enhanced healthcare infrastructure and strategic partnerships aimed at improving vaccine accessibility[1].

Competitive Landscape

The TCV vaccines market is competitive, with other players like GSK plc., Sanofi, Bharat Biotech, and BioFarma. However, Vivotif's strong brand recognition and proven efficacy give it a significant edge in the market[1].

Regional Growth and Demand

The demand for Vivotif varies regionally, with higher demand in areas where typhoid fever is more prevalent. The market growth is also influenced by the expansion of healthcare infrastructure and the adoption of inorganic growth strategies by pharmaceutical companies[4].

Innovative Solutions and Future Outlook

The commitment to innovative vaccine solutions and the push for improving vaccine accessibility are expected to further propel the market development of Vivotif. As international travel continues to rebound, the demand for travel vaccines, including Vivotif, is anticipated to increase, contributing to the overall growth of the TCV vaccines market[3].

Key Takeaways

• Market Dominance: Vivotif holds a significant market share due to its strong brand recognition and efficacy.
• Financial Growth: Revenue from Vivotif is expected to grow as part of Bavarian Nordic's expanding travel health segment.
• Challenges: Limited supply chains and varying regional demand are key challenges.
• Government Initiatives: Public health programs and government initiatives drive the market for Vivotif.
• Competitive Edge: Vivotif's proven efficacy and brand recognition give it a competitive advantage.

Frequently Asked Questions (FAQs)

1. What is Vivotif, and how does it work? Vivotif, or Ty21a, is an oral typhoid vaccine that provides protective immunity against typhoid fever by inducing an immune response without causing the disease.

2. Who are the key players in the TCV vaccines market? Key players include Bavarian Nordic, GSK plc., Sanofi, Bharat Biotech, and BioFarma.

3. What are the main drivers of the TCV vaccines market? The main drivers include increasing government initiatives, rising awareness of typhoid's prevalence, enhanced healthcare infrastructure, and strategic partnerships.

4. How has the COVID-19 pandemic affected the market for Vivotif? The pandemic led to a temporary stock-out situation but also highlighted the importance of travel vaccines, leading to a rebound in demand as international travel resumes.

5. What are the future projections for the TCV vaccines market? The market is expected to reach USD 935.9 million by 2031, growing at a CAGR of 12.4% from 2024 to 2031.

Cited Sources:

1. Coherent Market Insights - TCV Vaccines Market - Size, Share, Trends & Industry Overview 2031
2. Bavarian Nordic - Bavarian Nordic Announces First Half 2023 Results
3. Bavarian Nordic - Annual Report 2023 - Protecting our tomorrow
4. Spherical Insights - TCV Vaccines Market Size, Share and Forecast to 2030